drugset / Trial / NCT06228404
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
NaSequentialOpen-labelTreatment
Summary
This is one center, single-arm, open-label investigator initiated trial to assess the safety and efficacy of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment for patients with refractory castration resistant prostate cancer, and the sample size is set to 7-18 subjects.
Timeline
- Start
- 2024-03-03
- Primary completion
- 2026-05
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enhanced autologous PSMA-CAR T | Unknown | 250000 cells/kg | — |
| Subject | Enhanced autologous PSMA-CAR T | Unknown | 750000 cells/kg | — |
| Subject | Enhanced autologous PSMA-CAR T | Unknown | 2e+06 cells/kg | — |